Get the Daily Brief
Latest Biotech News
AI drug development scales: Formation Bio builds; Latent Labs designs biologics
Formation Bio outlined its AI‑native hub‑and‑spoke model to accelerate clinical development, telling investors and partners the platform can cut cost and time across trial design, execution and...
Priovant’s brepocitinib posts robust midstage gains in rare skin disease
Roivant spinout Priovant and its backers—including Pfizer—reported Phase 2 results showing brepocitinib achieved statistically and clinically meaningful improvements in cutaneous sarcoidosis,...
New tumor‑targeting strategies: CRISPR exploits oncogene amplifications; Wistar crafts dual‑action conjugate
A Spanish research consortium unveiled a CRISPR‑based gene‑editing approach that selectively targets tumors bearing oncogene amplifications, exploiting those amplifications as vulnerabilities to...
Adaptive Biotechnologies lifts MRD outlook — ClonoSeq adoption accelerates
Adaptive Biotechnologies raised its 2026 guidance as demand for its ClonoSeq minimal residual disease (MRD) assay continues to expand. Management forecasted 20%+ MRD revenue growth and said...
Hims pushes compounded Wegovy — federal scrutiny mounts
Telehealth firm Hims & Hers began selling a compounded version of Novo Nordisk’s newly approved Wegovy pill, prompting immediate regulatory and industry backlash. The move has drawn public...
White House rolls out TrumpRx — pharma signs on
The White House launched TrumpRx, a direct-to-consumer drug pricing platform, and several major manufacturers immediately joined with discount programs. Officials positioned the platform as a way...
Biotech IPO rebound: Eikon, Agomab, SpyGlass raise fresh capital
Biotech deal activity accelerated this week with several drug developers completing high‑profile public offerings to fund clinical programs. Eikon Therapeutics priced an upsized IPO that will...
UniQure pauses Fabry gene therapy dosing after liver toxicities
UniQure has paused mid and high dose cohorts in its AAV gene therapy trial for Fabry disease after two patients experienced grade 3 liver enzyme elevations. The company reported the dosing holds...
Bayer’s asundexian cuts secondary stroke risk — bleeding unchanged
Bayer disclosed Phase 3 results showing its Factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke by about 26% versus control without increasing bleeding rates. The company...
Adaptive Biotechnologies projects MRD growth as ClonoSeq adoption rises
Adaptive Biotechnologies forecasted robust growth for its minimal residual disease (MRD) business in 2026, projecting at least 20% year‑over‑year revenue expansion driven by wider adoption of its...
Illumina leans into clinical sequencing — small M&A adds optionality
Illumina reported a Q4 revenue uptick driven by clinical sequencing consumables and disclosed a $50 million purchase of short‑read sequencing-by-binding IP from PacBio to broaden strategic...
Priovant’s brepocitinib posts strong Phase 2 results in cutaneous sarcoidosis
Roivant spinout Priovant Therapeutics reported Phase 2 data showing its TYK2/JAK1 inhibitor brepocitinib significantly outperformed placebo in a small trial for cutaneous sarcoidosis, delivering...
Generate files for IPO after rapid AI-driven progress
Generate: Biomedicines, a Flagship Pioneering‑backed AI-driven drug developer, filed for an initial public offering after rapidly advancing programs and dosing its first Phase 3 patient. The S‑1...
AI-native drugmakers scale: Latent Labs, Formation Bio press design-to-clinic edge
Startups are sharpening AI-first models to accelerate biologics and clinical development. Latent Labs, formed by ex-DeepMind scientists, is marketing AI models that output drug-like biologics...
uniQure pauses dosing after liver toxicities: Fabry gene therapy trial hit
uniQure halted mid- and high-dose cohorts in its AAV gene therapy trial for Fabry disease after two patients experienced dose-limiting toxicities including grade 3 liver enzyme elevations. The...
Hims sells compounded Wegovy pill...FDA warns and makers threaten suits
Telehealth company Hims & Hers began offering a compounded version of Novo Nordisk’s newly approved Wegovy oral formulation, prompting public rebukes and legal threats from Novo and enforcement...
Biotech IPO wave returns: Eikon and Agomab/SpyGlass raise hundreds of millions
Eikon Therapeutics priced an upsized IPO that will raise roughly $381 million to advance its cancer drug candidates, while Agomab Therapeutics and SpyGlass Pharma together raised about $350...
Priovant’s brepocitinib posts strong Phase 2 results — rare skin disease responds
Priovant Therapeutics, a Roivant spinout supported by Pfizer‑origin assets, reported that brepocitinib significantly outperformed placebo in a Phase 2 trial for cutaneous sarcoidosis. The...
Bayer’s asundexian cuts recurrent stroke risk 26% — Phase 3 surprise
Bayer revealed Phase 3 results showing the oral Factor XIa inhibitor asundexian reduced secondary ischemic stroke by 26% without increasing bleeding, according to company disclosures and...
Adaptive Biotechnologies projects MRD boom: ClonoSeq adoption fueling 2026 growth
Adaptive Biotechnologies raised its 2026 outlook, forecasting at least 20% revenue growth in its minimal residual disease (MRD) business driven by adoption of its ClonoSeq assay and expanded use...